Cartesian Therapeutics, Inc. (United States)
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2016-01-01
- Employees
- 11
- Market Cap
- $300.2M
Clinical Trials
10
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (10 trials with phase data)• Click on a phase to view related trials
Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis
- Conditions
- Myasthaenia Gravis
- Interventions
- Biological: Decartes-08Other: Placebo Drug
- First Posted Date
- 2025-01-29
- Last Posted Date
- 2025-07-11
- Lead Sponsor
- Cartesian Therapeutics
- Target Recruit Count
- 100
- Registration Number
- NCT06799247
- Locations
- 🇺🇸
A40, Tucson, Arizona, United States
🇺🇸A13, Carlsbad, California, United States
🇺🇸A12, Amherst, New York, United States
Descartes-15 for Patients With Relapsed/Refractory Multiple Myeloma
- Conditions
- Refractory Multiple MyelomaRelapsed Multiple Myeloma
- Interventions
- First Posted Date
- 2024-03-12
- Last Posted Date
- 2025-05-29
- Lead Sponsor
- Cartesian Therapeutics
- Target Recruit Count
- 4
- Registration Number
- NCT06304636
- Locations
- 🇺🇸
Center for Cancer and Blood Disorders (AON), Bethesda, Maryland, United States
Descartes-08 for Patients With Systemic Lupus Erythematosus
- First Posted Date
- 2023-09-14
- Last Posted Date
- 2025-04-16
- Lead Sponsor
- Cartesian Therapeutics
- Target Recruit Count
- 30
- Registration Number
- NCT06038474
- Locations
- 🇺🇸
Profound Research LLC, Oceanside, California, United States
Descartes-25 in Relapsed/Refractory Multiple Myeloma
- First Posted Date
- 2021-11-09
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- Cartesian Therapeutics
- Target Recruit Count
- 9
- Registration Number
- NCT05113342
- Locations
- 🇺🇸
Louisiana State University Health Science Center at Shreveport, Shreveport, Louisiana, United States
🇺🇸Center for Cancer and Blood Disorders, Bethesda, Maryland, United States
🇹🇷Saglik Bilimleri Universitesi, Ankara, Anatolia, Turkey
Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy
- First Posted Date
- 2021-03-25
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- Cartesian Therapeutics
- Target Recruit Count
- 13
- Registration Number
- NCT04816526
- Locations
- 🇺🇸
University of California Irvine, Orange, California, United States
🇺🇸Sarah Cannon Research Institute at Tennessee Oncology, Nashville, Tennessee, United States
- Prev
- 1
- 2
- Next
News
CAR T-cell Therapy Pipeline Surges with 180+ Companies Advancing Novel Cancer Treatments
The CAR T-cell therapy pipeline has experienced significant growth, with over 180 companies actively developing more than 200 innovative cell therapy candidates across various stages of clinical development.
Cartesian Therapeutics' Descartes-08 Shows Promise in Myasthenia Gravis Phase 3 Trial
Cartesian Therapeutics secured FDA agreement for Phase 3 trial of Descartes-08 in myasthenia gravis, potentially leading to BLA submission.
Novel Therapies and Vaccines Poised to Reshape Community Pharmacy in 2025
Insulin icodec, a once-weekly basal insulin analog, demonstrated positive safety and efficacy in phase 3 trials for type 2 diabetes, potentially reducing injection burden and improving adherence.
Cartesian Therapeutics Advances mRNA Cell Therapies for Autoimmune Diseases
Cartesian Therapeutics is set to begin Phase 3 AURORA trial of Descartes-08 for myasthenia gravis in the first half of 2025.
CAR T-Cell Therapy Shows Promise in Treating Autoimmune Diseases: Clinical Trials and Future Directions
UChicago Medicine launched a Phase 2 clinical trial to explore CAR T-cell therapy for systemic lupus erythematosus, inflammatory myositis, and systemic sclerosis.
Cartesian Therapeutics Advances Myasthenia Gravis Treatment with Phase 3 Trial of Descartes-08
Cartesian Therapeutics is set to begin a Phase 3 trial (AURORA) for Descartes-08, an mRNA CAR-T therapy, in patients with acetylcholine receptor autoantibody positive (AChR Ab+) myasthenia gravis (MG).
Cartesian Therapeutics' Descartes-08 Receives FDA Agreement for Phase 3 Myasthenia Gravis Trial
Cartesian Therapeutics received FDA agreement under the Special Protocol Assessment for its Phase 3 AURORA trial of Descartes-08 in myasthenia gravis.
FDA Grants Rare Pediatric Disease Designation to Cartesian's Descartes-08 for Juvenile Dermatomyositis
The FDA has granted Rare Pediatric Disease Designation to Cartesian Therapeutics' Descartes-08 for treating juvenile dermatomyositis (JDM).
Cartesian Therapeutics' Descartes-08 Shows Promise in Myasthenia Gravis Phase 2b Trial
Cartesian Therapeutics' Descartes-08 met the primary endpoint in a Phase 2b trial for myasthenia gravis, demonstrating statistically significant improvement in MGC scores.
Cartesian Therapeutics Doses First Patient in Phase 1 Trial of mRNA CAR-T Therapy Descartes-15 for Multiple Myeloma
Cartesian Therapeutics initiated a phase 1 clinical trial for Descartes-15, a novel mRNA-engineered CAR-T therapy, in relapsed/refractory multiple myeloma patients.